The disclosure relates to a compound 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide or a pharmaceutically acceptable salt thereof, intended for treatment of Alzheimer's disease and other types of dementia.
An H3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease